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Background and purpose: The absolute number of new cancer patients that will require at least one course
of radiotherapy in each country of Europe was estimated.
Material and methods: The incidence and relative frequency of cancer types from the year 2012 European
Cancer Observatory estimates were used in combination with the population-based stage at diagnosis
from ﬁve cancer registries. These data were applied to the decision trees of the evidence-based indica-
tions to calculate the Optimal Utilization Proportion (OUP) by tumour site.
Results: In the minimum scenario, the OUP ranged from 47.0% in the Russian Federation to 53.2% in
Belgium with no clear geographical pattern of the variability among countries. The impact of stage at
diagnosis on the OUP by country was rather limited. Within the 24 countries where data on actual use
of radiotherapy were available, a gap between optimal and actual use has been observed in most of
the countries.
Conclusions: The actual utilization of radiotherapy is signiﬁcantly lower than the optimal use predicted
from the evidence based estimates in the literature. This discrepancy poses a major challenge for policy
makers when planning the resources at the national level to improve the provision in European countries.
 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2015) xxx–xxxThe estimated number of new cancer patients that require
radiotherapy is a key parameter for planning the resources needed
in a speciﬁc country in the framework of a cancer controlprogramme. Most commonly, this calculation has been carried
out using a speciﬁc proportion, typically the ‘gold standard’ of
50%, of the incident cases that would require radiotherapy at leastMedical
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2 Optimal utilization radiotherapy in Europeonce during the course of his/her cancer. Although several more
reﬁned approaches have been developed to estimate this propor-
tion developed by the Australian Collaboration for Cancer
Outcomes Research and Evaluation (CCORE) can be considered
the most optimal, as this approach involves a comprehensive and
evidence-based analysis of all cancer sites [1] and has recently
been updated [2]. In Australia this resulted in an optimal utiliza-
tion proportion of 48.3%, that is, 48.3% of all incident cancer cases
would require a course of radiotherapy at least once in the course
of the disease.
In addition to the indications for radiotherapy in each clinical
pathway, key parameters to evaluate the OUP of radiotherapy are
the relative frequencies of cancer types as well as the stage at diag-
nosis [3].
The differences across European countries in cancer incidence,
both in absolute number and in relative frequency of each tumour
are signiﬁcant [4]. Thus, it is of crucial importance to take into
account the existing differences in the relative frequency of various
cancers across Europe when calculating the OUP for each individ-
ual country, and to evaluate its impact on the absolute number
of new cancer patients that will require radiotherapy.
The objective of this study is a logical step forward within the
ESTRO-HERO project, which is an ESTRO supported activity aimed
at developing a knowledge base and a model for the health eco-
nomic evaluation of radiation oncology in the European countries.
Analyses of the resources available in the European countries were
recently published [5–7]. This paper evaluates the evidence-based
country-speciﬁc demand for radiotherapy across Europe in order to
allow all stakeholders to be able to estimate the capital and human
resources required to deliver an appropriate radiotherapy service.Material and methods
In order to estimate the absolute number of new cancer patients
that will require radiotherapy in each country, the number of new
cancer cases estimated for the year 2012, was combined with the
overall OUP of radiotherapy in different European countries.
The country speciﬁc absolute number of new cancer cases has
been obtained for the countries included in the European Cancer
Observatory (ECO) database, estimated for the year 2012, and
based on projections from the population based cancer registries
available [4]. For non-Hodgkins lymphoma and head and neck can-
cers, which required further subdivision by subtypes, data from
population based cancer registries have been used.
The OUP has been calculated using the methodology developed
by the Australian Collaboration for Cancer Outcomes Research and
Evaluation (CCORE) group, using evidence based indications for
radiotherapy for all tumour sites with more than 1% incidence
[1,2]. Brieﬂy summarized, the CCORE team reviewed all the rele-
vant published evidence-based guidelines and the scientiﬁc
literature, updated until 2012, regarding the indications for radio-
therapy for different tumour sites and accounting for the entire
range of relevant stages at diagnosis. Indication for radiotherapy
was deﬁned as meaning it was the treatment of choice because
there was evidence that radiotherapy has a superior clinical out-
come (either measured by survival, quality of life, lower toxicity
proﬁle or better local control) compared to the alternative modal-
ities or no treatment, provided that the patient is ﬁt enough to
undergo treatment. Based on these data, the CCORE team devel-
oped a decision tree model to estimate, by tumour site and for
all cancers overall, the proportion of patients in whom external
beam radiotherapy would be recommended at some stage during
the course of the disease. Pathway probabilities included the distri-
bution of cancer incidence by tumour site, stage at diagnosis and
relevant clinical characteristics of patients for each tumour (agePlease cite this article in press as: Borras JM et al. The optimal utilization propor
analysis. Radiother Oncol (2015), http://dx.doi.org/10.1016/j.radonc.2015.04.01and variations in performance status). The structure of the decision
trees for each cancer site as well as the evidence supporting each
clinical alternative and the corresponding probability of occur-
rence are available in the original report [8]. As neither retreat-
ments nor brachytherapy were included in the CCORE decision
trees, the focus of this analysis is exclusively on the optimal pro-
portion of cancer patients receiving at least one course of external
beam radiotherapy.
The relative frequency of each tumour is not only a necessary
input for the calculation of the country-speciﬁc OUP, but also the
main determinant of the inter-country OUP variation [3]. As shown
in Table 1, which includes the relative percentages from the 12
most frequent cancers in Europe according to the ECO [4], the rel-
ative frequency varies signiﬁcantly among countries. Stage at diag-
nosis, the other essential input parameter in the OUP calculation
model, was not readily available in many cancer registries [9]. In
a previous paper we have however shown that only a small part
of the variability in overall OUP for radiotherapy was found among
four European countries that have stage data available (i.e.
Belgium, The Netherlands, Greater Poland region of Poland, and
Slovenia), can be explained by the differences in stage distribution
[3]. It can therefore be considered reasonable that the range of
stage values from these four countries is representative of the
other European countries. Hence, in order to assess the impact of
stage distribution on the OUP in all ECO countries, we have applied
the four different population based stage distributions, in addition
to the Australian stage data, to each individual European country.
The country speciﬁc range of OUP values are presented for all can-
cers combined.
All OUP calculations are carried out using the year 2012 as ref-
erence for the incidence and frequency data. The available data for
stage at diagnosis from the population cancer registries are for the
years 2009–11, depending on the cancer registry [3].
The number of radiotherapy courses obtained by combining the
estimated number of new cancer cases for 2012 with the OUP by
country, can be considered the ‘optimal demand for radiotherapy’
in each individual country. This number has been compared to
the annual courses of radiotherapy delivered from the HERO data-
base (provided by the National Societies, available years ranging
from 2009 to 2011; with the corrections of the data included) [5]
in order to assess the gap between optimal and actual delivered
treatment courses.
Data on the number of actual courses delivered were provided
in different ways: without including retreatments in several coun-
tries while other countries included retreatments in the total num-
ber of courses. To allow comparison between optimal and actual
courses, retreatments should be excluded. Therefore, in the coun-
tries where retreatments were included, the courses were adjusted
by a factor of 0.80 in order to compensate for the increment of 25%
typically applied for retreatments [5]. This approach has been
taken due to the lack of consistent data across European countries
on the retreatments carried out; until now only local analyses have
been published [10–12], mostly from outside Europe. Thus, the
option here has been to focus on data for new cancer cases. All cal-
culations were carried out using the Tree Age software.Results
The variability of overall OUP by country, adjusted by stage at
diagnosis from the ﬁve population-based cancer registries, is
presented in Fig. 1. The variation by country is typically limited
to between 1% and 2%.
The numbers of new cancer cases estimated for the year 2012 in
the 40 European countries included in this study are presented in
Table 2, jointly with the calculated OUP by country. This OUP istion of external beam radiotherapy in European countries: An ESTRO-HERO
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Table 1
Estimated percentage of cancer cases by most frequent tumour site and country, 2012.
Country Bladder Breast Corpus
uteri
Kidney Large
bowel
Oral
cavity
Lung Melanoma of
skin
Non-Hodgkin
lymph
Pancreas Prostate Stomach All
sites
Albania 5.9 14.3 3.1 3.2 4.8 3.0 15.4 0.5 0.4 2.8 4.7 11.7 100.0
Austria 5.3 12.8 2.2 3.2 11.9 2.8 11.1 3.2 2.9 3.9 14.2 3.2 100.0
Belarus 3.3 11.7 4.4 4.9 12.3 3.8 12.4 1.8 1.6 2.5 6.6 9.1 100.0
Belgium 6.7 15.8 2.3 2.7 13.3 2.9 11.9 3.0 3.2 2.0 14.4 2.2 100.0
Bosnia 4.7 11.6 3.3 2.9 11.2 2.9 17.4 1.1 1.2 2.6 7.0 5.3 100.0
Bulgaria 5.2 12.3 4.0 2.7 15.4 2.7 12.3 1.4 1.7 3.9 5.7 5.2 100.0
Croatia 4.6 11.5 2.6 3.6 14.0 3.0 13.4 2.9 2.4 3.0 8.8 4.2 100.0
Cyprus 6.6 17.6 2.7 1.3 12.9 0.9 8.0 1.5 3.4 2.2 14.0 2.7 100.0
Czech Republic 4.3 11.9 3.3 5.7 14.5 2.6 11.6 3.8 2.2 3.7 11.9 2.8 100.0
Denmark 4.9 14.5 2.1 2.1 13.4 2.5 12.6 4.4 2.9 2.8 14.4 1.7 100.0
Estonia 3.4 10.8 3.4 4.6 12.9 2.3 10.3 2.7 2.1 3.1 16.7 6.0 100.0
Finland 3.8 15.7 3.0 3.1 10.2 2.0 8.8 4.2 4.2 4.0 18.9 2.3 100.0
France 3.0 14.6 1.8 3.0 11.0 3.0 10.8 2.7 3.1 2.5 19.8 1.8 100.0
FYR Macedonia 5.1 15.7 6.1 1.4 10.7 1.4 17.3 2.0 1.1 3.4 6.0 7.4 100.0
Germany 5.8 14.5 2.3 3.8 12.9 3.2 10.3 3.4 3.0 3.3 13.8 3.2 100.0
Greece 6.8 12.0 2.1 2.7 9.5 1.4 16.8 1.2 1.1 3.8 7.9 3.6 100.0
Hungary 5.3 10.1 1.6 3.1 16.7 5.3 18.4 2.2 2.0 3.7 6.3 3.9 100.0
Iceland 4.6 15.5 2.1 3.1 10.8 1.8 11.2 3.5 3.2 2.0 18.8 1.9 100.0
Ireland 3.2 13.9 1.8 2.7 12.3 1.8 10.9 4.1 3.4 2.5 18.2 2.3 100.0
Italy 5.2 14.3 2.4 3.2 13.6 1.6 10.5 2.8 3.5 3.0 12.6 3.7 100.0
Latvia 4.1 11.1 3.8 4.3 11.1 2.1 11.4 2.2 1.8 3.6 14.3 6.2 100.0
Lithuania 3.9 10.2 3.9 5.3 10.7 2.6 10.7 1.9 2.4 3.3 10.4 6.0 100.0
Luxembourg 3.9 14.5 4.6 2.8 12.5 2.6 10.5 3.5 2.7 2.7 13.6 2.7 100.0
Malta 6.9 16.5 3.4 3.0 14.1 2.7 9.5 1.9 2.6 3.9 10.6 3.6 100.0
Moldova 3.5 11.2 3.5 2.3 15.3 4.4 12.5 1.2 2.1 4.4 4.4 6.2 100.0
Montenegro 4.5 12.3 3.4 2.8 12.5 3.1 17.1 1.9 1.7 2.8 7.2 4.2 100.0
Norway 4.9 10.2 2.7 2.8 13.9 1.9 10.1 5.3 3.2 2.6 20.5 1.7 100.0
Poland 5.2 11.3 3.9 3.4 12.8 3.3 17.2 1.7 1.7 3.3 7.2 4.0 100.0
Portugal 5.8 12.4 3.0 2.0 14.5 4.2 8.5 2.2 3.7 2.5 13.5 6.1 100.0
Romania 4.9 11.4 2.0 2.5 13.0 4.7 14.8 1.4 2.0 3.9 5.8 5.2 100.0
Russia 3.0 12.5 4.6 4.2 13.1 3.2 12.2 1.9 1.7 3.2 5.9 8.4 100.0
Serbia 4.4 12.8 3.4 2.7 13.1 3.1 17.2 2.4 2.1 3.0 7.4 3.5 100.0
Slovakia 3.9 11.0 3.9 4.4 16.5 4.1 10.5 3.4 2.4 3.7 8.0 3.7 100.0
Slovenia 4.0 11.0 2.7 3.5 14.1 2.8 11.9 4.7 2.6 3.3 13.7 4.1 100.0
Spain 6.4 11.7 2.4 3.0 15.0 2.8 12.4 2.3 2.8 3.0 12.9 3.6 100.0
Sweden 4.7 13.1 2.8 2.2 12.6 1.9 7.7 5.8 3.2 1.9 23.0 1.6 100.0
Switzerland 5.0 13.7 2.4 2.3 11.6 2.8 10.1 5.9 3.6 2.8 18.7 1.6 100.0
The Netherlands 3.2 14.9 2.2 2.9 14.9 2.2 12.8 5.1 3.5 2.3 14.2 2.1 100.0
Ukraine 3.5 11.7 4.9 3.7 13.5 4.1 12.2 2.0 1.5 3.4 4.7 8.1 100.0
UK 2.7 16.0 2.6 3.0 12.4 2.3 12.3 4.4 3.6 2.7 13.9 2.0 100.0
Europe 4.4 13.5 2.9 3.3 13.0 2.9 11.9 2.9 2.7 3.0 12.1 4.1 100.0
Source: European Cancer Observatory (www. eco.iarc.fr/).
J.M. Borras et al. / Radiotherapy and Oncology xxx (2015) xxx–xxx 3calculated by applying each stage data set, thus obtaining 5
different OUPs by country, and the highest and the lowest OUP
are presented in the table.
Globally speaking, out of 3.41 million new cancer cases diag-
nosed in European countries in 2012, 1.74 million patients
(unweighted average percentage of OUP between the highest and
lowest stages of 51.0%) should have received at least one radiother-
apy course following the evidence-based approach used in the pre-
sent analysis. Using the stage distribution that provides the lower
estimate of OUP, the variation in OUP by country ranged from the
lowest in the Russian Federation with 47.0% to the highest in
Belgium with 53.2%; or an absolute 6.2% difference is observed.
No clear geographical pattern can be observed with respect to
the OUP distribution.
The available numbers of radiotherapy courses by country from
the HERO database are also presented in Table 2. The gap between
the actual number and the optimal utilization obtained from the
evidence-based model, expressed as a percentage, is calculated.
This gap is presented in Fig. 2 as a percentage of the total number
of patients that would have required, at least once, a radiotherapy
course according to the OUP by country. Globally speaking, 4 coun-
tries treated at least 80% of the optimal indications for radiother-
apy and 11 countries not even reached 70% of the patients
optimally indicated. Of interest is that just one country reports aPlease cite this article in press as: Borras JM et al. The optimal utilization propor
analysis. Radiother Oncol (2015), http://dx.doi.org/10.1016/j.radonc.2015.04.01utilization of radiotherapy in excess to the ﬁgures proposed by
the OUP range.Discussion
The unique contribution of this study is the estimate of the opti-
mal utilization proportion (OUP) of radiotherapy for 40 European
countries. For each country, speciﬁc relative frequencies of the
most common cancers were taken into account as well as realistic
estimates of the ranges of stages at diagnosis from population
based cancer registries. Previous attempts to calculate the number
of new cancer cases that would require radiotherapy have only
considered a unique proportion, usually 50% of new cancer cases
plus 25% retreatments, 62.5% in total [13,14], all following the rec-
ommendations previously presented in the QUARTS project [15]
that was based on the initial CCORE study.
Although the information on the distribution of cancer stages at
diagnosis was not available for the majority of countries, which is a
shortcoming, stage at diagnosis data from ﬁve population based
cancer registries allowed us to take into account this second factor
in the estimation of the OUP. The difﬁculties in collecting data on
stage in population cancer registries are well known [9] and the
number of registries with this information available is rathertion of external beam radiotherapy in European countries: An ESTRO-HERO
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Fig. 1. Range of values for overall optimal utilization proportion by country (in percentages of total cancer incidence).
4 Optimal utilization radiotherapy in Europelimited. However, the four national sets of stage data together with
those from Australia allowed us to create a range of values that
could be considered as encompassing the majority of health ser-
vices across Europe. In addition, we have assessed, in a previous
paper, the differential impact of relative frequencies of tumours
and stage distributions in ﬁve countries. The fact is that the relative
frequency of tumours showed a higher impact on the OUP than
stage distribution due to its more general inﬂuence on the decision
trees [3]. The stage is very relevant to OUP in some speciﬁc tumour
sites, such as rectal or cervical cancer, but not in others which sig-
niﬁcantly inﬂuence the demand for radiotherapy, such as breast or
prostate cancer. Thus, it could be concluded that the lack of stage
data for most countries has only a limited impact on the estimated
national OUPs and the size of the impact can be judged from the
rather small inﬂuence of the different stage distributions from
the ﬁve countries for which data were available.
The approach applied here has shown that the variation in fre-
quency distribution of individual cancer sites signiﬁcantly affects
the OUP calculation and hence the estimation of demand for radio-
therapy with the concomitant resources – equipment and person-
nel – needed to cope with these new cancer cases. For instance, and
using Belgium as an example, the OUP is 53.3%; using its own stage
data [3]; a difference of 5.0% from the Australian estimate of 48.3%
[2]. This difference represents 3267 additional patients with an
indication for radiotherapy (excluding retreatments), implying
the need for 7.8 linear accelerators, based on the average through-
put of 420 courses of radiotherapy per MV unit in the European
countries or 8.5 based on the Belgian average number of patients
treated on a linear accelerator [5]. This illustrates how the
differences calculated, even if they may seem small, could have a
substantial impact on the calculation of the resources needed.
The same example for Spain would result in an extra 7.2 linear
accelerators. It can be concluded that the country-speciﬁc adjust-
ment for the epidemiological situation by country may result in a
more reliable estimate, which would provide a better basis to
estimate the need for equipment and staff for radiotherapy, and
consequently, more accurate planning at the national level.Please cite this article in press as: Borras JM et al. The optimal utilization propor
analysis. Radiother Oncol (2015), http://dx.doi.org/10.1016/j.radonc.2015.04.01The discrepancy between evidence based recommendations
and the reality of the provision of health services poses a challenge
for policy makers, although the range of discrepancies varies sig-
niﬁcantly among countries. The relevant question in this frame-
work is why the actual utilization of radiotherapy is lower than
it should be according to the evidence. In fact, several recent
studies carried out in countries with high survival rates, a good
indicator of quality of cancer care [16], such as the Netherlands
or Norway, have shown that the proportion of patients receiving
radiotherapy treatment is lower than expected. For instance,
between 1997 and 2008, external beam radiotherapy was used in
only 25% of the patients with a diagnosis of prostate cancer in
the Netherlands [17], markedly lower than the OUP of about 60%,
even taking into account that the utilization data from the
Netherlands were restricted to the ﬁrst 6 months after diagnosis.
The situation was similar in non-small cell lung cancer [18] with
40% actual utilization, far below the calculated 80%; but it was
not the case in rectal cancer, which showed a 71% of utilization
[19] slightly higher than expected from CCORE model.
Furthermore, in Norway [10], a lower utilization of radiotherapy
during the ﬁrst 5 years after diagnosis was found for all tumours
in comparison with the evidence based recommendations. They
also analyzed speciﬁcally the most frequent indications (breast,
prostate, lung, colorectal, and head and neck cancers) and they
observed a lower utilization than predicted, with the exception
of breast cancer.
The discrepancy between evidence based OUPs and actual use
of radiotherapy could be explained by different factors that are
relevant when planning investments in radiotherapy resources.
 First of all, reduced use of radiotherapy has been associated
with limitations due to geographical access [20], with speciﬁc
impact on palliative radiotherapy [21].
 Second, the presence of comorbidity, particularly when
combined with older age, is usually associated with the
under-utilization of radiotherapy [22,23]. It should be recog-
nized, however, that in speciﬁc indications such as muscletion of external beam radiotherapy in European countries: An ESTRO-HERO
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Table 2
Summary of the assessment of incident cancer patients that will require radiotherapy treatment according to the evidence based utilization and excluding the need for re-
treatment.
Country Total cancers (n)a OUP (%)b Optimal RT courses (n) Actual RT courses (n)c Actual/optimal RT courses
(%)
Min. Max. OUP min. OUP max. OUP min. OUP max.
Albania 7143 52.6 54.3 3758 3879 2195 58.4 56.6
Austria 41,117 49.0 50.3 20,155 20,698 17,185 85.3 83.0
Belarus 32,422 48.5 50.3 15,738 16,293 NA
Belgium 65,345 53.2 54.8d 34,792 35,799 27,738 79.7 77.5
Bosnia Herzegovina 9911 52.8 54.4 5236 5395 NA
Bulgaria 32,053 51.3 53.0 16,434 16,977 11,035 67.1 65.0
Croatia 22,890 51.2 52.7 11,717 12,055 NA
Cyprus 3438 51.0 52.3 1753 1799 NA
Czech Republic 57,627 48.5 50.2 27,943 28,945 26,104 93.4 90.2
Denmark 36,119 52.8 54.3 19,064 19,600 14,144 74.2 72.2
Estonia 6117 49.1 50.8 3004 3104 1698 56.5 54.7
Finland 28,428 52.1 53.4 14,810 15,189 NA
France 371,676 51.9 53.3 192,769 198,107 149,738 77.7 75.6
FYR Macedonia 7330 52.6 54.3 3856 3981 NA
Germany 493,780 50.1 51.6 247,419 254,735 NA
Greece 40,971 52.5 54.2 21,523 22,213 NA
Hungary 50,475 50.3 51.9 25,412 26,209 15,961 62.8 60.9
Iceland 1449 50.7 51.8 734 750 476 64.8 63.5
Ireland 20,808 51.5 52.9 10,714 11,017 6,698 62.5 60.8
Italy 354,456 48.2 49.3 170,821 174,764 NA
Latvia 10,347 49.9 51.4 5166 5315 NA
Lithuania 14,520 49.9 51.5 7242 7483 5,014 69.2 67.0
Luxembourg 2476 50.6 52.0 1252 1289 944 75.4 73.3
Malta 1,902 51.9 53.3 988 1014 535 54.2 52.8
Moldova 9894 50.2 52.1 4969 5151 NA
Montenegro 2115 52.2 53.8 1105 1139 1200 108.6 105.4
Netherlands 93,448 52.3 53.9e 48,886 50,324 44,546 91.1 88.5
Norway 28,214 49.0 50.5 13,818 14,248 10,786 78.1 75.7
Poland 152,216 52.0 53.4f 79,139 81,294 58,800 74.3 72.3
Portugal 49,174 49.7 51.1 24,438 25,151 14,366 58.8 57.1
Romania 78,760 50.0 51.8 39,383 40,805 NA
Russian Federation 458,382 47.0 48.6 215,507 222,922 NA
Serbia 42,221 52.2 53.8 22,050 22,733 NA
Slovakia 24,045 48.2 50.2 11,599 12,071 NA
Slovenia 11,457 49.6 51.3g 5680 5874 3603 63.4 61.3
Spain 215,534 49.7 51.1 107,018 110,159 78,820 73.7 71.6
Sweden 50,481 51.4 52.8 25,928 26,662 18,142 70.0 68.0
Switzerland 42,046 50.6 52.0 21,294 21,865 15,200 71.4 69.5
Ukraine 140,999 50.2 52.1 70,811 73,403 NA
United Kingdom 297,227h 53.0 54.4 157,414 161,760 105,531i 67.0 65.2
Global 3,409,013 50.2 51.7 1,711,337 1,762,171
NA: Not-available.
a All cancers excl. non-melanoma skin cancer. Globocan 2012.
b OUP: optimal utilization proportion.
c Excluding re-treatment.
d OUP calculated from population based stage at diagnosis from country cancer registry: 53.3%.
e OUP calculated from population based stage at diagnosis from country cancer registry: 52.3%.
f OUP calculated from population based stage at diagnosis from country cancer registry: 53.4%.
g OUP calculated from population based stage at diagnosis from country cancer registry: 50.3%.
h Scotland not included.
i Scotland not available.
J.M. Borras et al. / Radiotherapy and Oncology xxx (2015) xxx–xxx 5invasive bladder cancer, where surgery is indicated, radiother-
apy could be the preferred option with increased utilization in
the elderly with comorbidity [24].
 Third, comparable effects were seen from patient-related
factors such as the lower socio-economic level [25].
 A fourth relevant aspect is the preference of the physician for
one therapeutic option over alternatives. In a paper published
some years ago urologists and radiation oncologists were pre-
sented with the same clinical scenarios in order to assess their
beliefs and therapeutic recommendations for prostate cancer.
The result was not surprising that the specialists recommend
the therapy that they deliver for the same clinical cases (72%
of the radiation oncologists believed that external beam radio-
therapy and surgery were equivalents while 93% of urologists
believed that radical prostatectomy was the preferred option).Please cite this article in press as: Borras JM et al. The optimal utilization propor
analysis. Radiother Oncol (2015), http://dx.doi.org/10.1016/j.radonc.2015.04.01Beyond the speciﬁc clinical example, the paper clearly showed
the bias favouring known clinical pathways that in some cases
could exclude radiotherapy, although there is an evidence base
for the indication [26]. Thus, lack of awareness, personal belief
or knowledge could be another reason for the lower use of a
particular treatment modality than expected considering
evidence based data.
 A ﬁfth factor is the shortage of resources, which resulted in
waiting lists, delays in initiation of radiotherapy and reduced
effectiveness of the treatment [20]. Such situations are unavoid-
ably destinated to translate into lower utilization of radiother-
apy. Shortage of resources is, at least in part, related to the
speciﬁc ﬁnancing structure within a country.
 This brings us to the last well-known factor that drives practice:
the prevailing reimbursement in the country and the ensuingtion of external beam radiotherapy in European countries: An ESTRO-HERO
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Fig. 2. Comparison between actual and optimal utilization of radiotherapy by country (expressed as a percentage of the actual and the optimal number of patients, excluding
retreatments).
6 Optimal utilization radiotherapy in Europeﬁnancial (dis)incentives. In the case of radiotherapy, reimburse-
ment mechanisms may play a role in the choice of treatment
complexity or fractionation, as has been observed when the
higher reimbursement of IMRT for prostate cancer fuelled its
use in the US, or when fee-for-service reimbursement endorsed
the use of more protracted schedules for the palliation of bone
metastases, thus limiting the evidence-based use of single frac-
tions [27,28]. Also, the fact that radiation oncology depends on
the referral pattern of other specialists, adds complexity to this
issue. But it is not impossible that, at the national level, the
intricate interplay of the ﬁnancing systems in oncology may
result in radiotherapy being less attractive than competing
oncologic treatment strategies.
Hence, translating evidence-based indications for radiotherapy
into clinical practice requires taking into account all the above fac-
tors, with an emphasis on organizational factors related to accessi-
bility and availability of capital resources and trained staff as well
as the promotion of appropriate indications in a multidisciplinary
framework of high quality cancer care, all endorsed by the appro-
priate ﬁnancing mechanisms.
In order to fully assess these results, some limitations should be
taken into account. The possible limitation of the OUP having been
estimated with stage distributions from only ﬁve population based
cancer registry data has been discussed above. Analyses, such as
the one presented, are inherently limited by the timely and com-
plete collection of data: for the estimates of the gap between actual
and optimal utilization, the latter refers to the year 2012 while the
data on actual utilization are not [5,6]. Variations in radiotherapy
activity are, however, extremely dependent on facilities being
opened or renovated and additional personnel being trained, both
typically spreading over long time periods. Hence we feel that the
impact of the differential timing of actual and calculated utilization
on the estimated gap should not be too important, with possible
local exceptions that could be included in the range of values
estimated for each country. The last serious limitation is that the
actual utilization is only available in about half of the countries.
Thus, the discussion about the gap is limited to those countriesPlease cite this article in press as: Borras JM et al. The optimal utilization propor
analysis. Radiother Oncol (2015), http://dx.doi.org/10.1016/j.radonc.2015.04.01that have data on this key aspect of the planning of radiotherapy
facilities and associated personnel. This point deserves careful con-
sideration by the health care decision makers as the lack of essen-
tial data may seriously hamper rational planning of radiotherapy
services.
In conclusion, the OUP for radiotherapy in the European
countries has been estimated from an evidence-based assessment
of the indications for radiotherapy, taking into account the differ-
ences in the relative frequency of cancer sites by country as well
as a range of population based data on stage at diagnosis from ﬁve
countries. A large discrepancy was observed between the actual
utilization and the optimal utilization of radiotherapy in
European countries, with less than 17% of countries treating at
least 80% of the optimal indications for radiotherapy and about
46% of the European countries not even reaching 70% of the
patients optimally indicated. These data should be taken into
account when planning the resources at the national level and
should support the development of guidelines for required
resources and for cancer control plans.Conﬂicts of interest
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